REFERRAL (ARTICLE 31): OMEGA-3 ACID ETHYL ESTERS – CONTAINING MEDICINAL PRODUCTS FOR ORAL IN USE IN SECONDARY PREVENTION AFTER MYOCARDIAL INFARCTION
13 juin 2019
Following a request from some marketing authorisation holders, the CHMP re-examined its original opinion and adopted its final opinion (omega-3 fatty acid medicines not effective in preventing further heart problems after a heart attack). The European Commission issued a final legally binding decision applicable in all EU Member States on 6 June 2019.
Vous avez aimé cet article ? Partagez le sur les réseaux sociaux :